Bio-Plex Multiplex AssaysFeatured WebinarsWebinars

A Rapid, Culture-Free Method to Determine 50% Neutralization Titer (NT50) Using the ACE2-Competitive Bio-Plex Pro SARS-CoV-2 Neutralization Antibody Assay

In this webinar, see how a Bio-Plex Pro Assay could provide a high-throughput culture-free NT50 determination method for current and future SARS-CoV-2 variants.
ArticlesBio-Plex Multiplex AssaysProduct Highlights

Measure Neutralizing Antibodies against Any SARS-CoV-2 Variant in 1 Day

Current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have reduced the severity of the coronavirus disease 2019 (COVID-19). However, the drastic and quick evolution of the virus poses challenges to the development of durable and efficacious therapeutics for vaccine and antibody developers alike. See how the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit speeds up the qualitative measurement of neutralizing antibodies (NAbs) against new SARS-CoV-2 variants, removing a roadblock in COVID-19 therapeutic development.
ZE5 cell analyzer article header image
ArticlesCell Biology

Leading the Way in Our Understanding of COVID-19: Peptide Megapool Assays

Understanding how T cells respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical in developing long-term therapeutic approaches, as well as helping inform strategies for future pandemics. Learn how one team at the La Jolla Institute for Immunology in San Diego, California, has been using novel T-cell activation assays to understand how our immune system responds to SARS-CoV-2.
ArticlesCell BiologyCOVID-19Drug Discovery and DevelopmentFeatured StoriesGeneral InterestResearch Highlights

Immune Surveillance in SARS-CoV-2 Vaccine Development

The ability to characterize the target of cell-mediated immune response is crucial during vaccine development. In studying the characterization of SARS-CoV-2 infection pathogenesis in humans, a research team identified neutralizing antibodies that provided context for vaccine antigen design. Discover how the ZE5 Cell Analyzer was used to detect activation-induced markers, measure intracellular cytokines, and identify spike protein–specific antibodies in a rapid, high-throughput manner.
ArticlesBio-Plex Multiplex AssaysCOVID-19Product Highlights

Introducing the Bio-Plex Pro Human IgG SARS-CoV-2 Serology Assays

Meet our newest product supporting the fight against SARS-CoV-2: the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel. This qualitative multiplex immunoassay kit quickly and efficiently detects IgG antibodies against four SARS-CoV-2 antigens (nucleocapsid, receptor binding domain, spike 1, and spike 2).
COVID-19General InterestPast WebinarsWebinars

Immunological Response Factors to SARS-CoV-2 in Acquired Immunity

Multiple publications report variation in the duration of acquired immunity to SARS-CoV-2. In this webinar, Bio-Rad scientists review these reports and discuss factors that influence longevity of acquired immunity. Learn about the mechanisms behind acquired immunity and how cytokine and chemokine activity, preexisting conditions, and more can affect immunity duration.
ArticlesBio-Plex Multiplex AssaysDrug Discovery and DevelopmentGeneral Interest

Multiplex Immunoassays in the Race for a COVID-19 Vaccine

In vaccine development, safety and efficacy are critical. Recent studies have shown that multiplex immunoassays offer a flexible way to monitor immune responses. With the ever-increasing pressure on scientists to develop a practical COVID-19 vaccine, multiplex immunoassays stand out as a proven tool.
COVID-19General InterestPast WebinarsWebinars

The Role of Aberrant Cytokine Activity in COVID-19 Disease

Presented by: Kenneth Oh, PhD, Collaborations, Applications, and New Technology Senior Global Manager
Kelly King, PhD, Field Application Specialist II
Brad VanderWielen, PhD, Field Application Specialist II
Candice Cox, Global Marketing Manager, Immunoassays

View on demand

Emerging reports from the COVID 19 pandemic include a spectrum of patient symptoms due to the host immune response. In this webinar, Bio-Rad scientists discuss early research and nascent hypotheses about the pathophysiology of SARS CoV 2–induced COVID 19 disease by evaluating cytokine and chemokine profiles, the role of chronic inflammation in comorbidities, and the arc of immune resolution of historical virulent pathogens, such as SARS and MERS.